Serum Proteomic Analysis of Multiple Myeloma Subjects Treated with Daratumumab Monotherapy

被引：0
|
作者：
Casneuf, Tineke [1 ]
Lysaght, Andrew [2 ]
LeFave, Clare [3 ]
Bald, Jaime [4 ]
Weiss, Brendan [5 ,6 ]
van de Donk, Niels W. C. J. [7 ]
Lokhorst, Henk M. [7 ]
Ahmadi, Tahamtan [4 ]
Sasser, A. Kate [4 ]
机构：
[1] Janssen Res & Dev, Beerse, Belgium
[2] Immuneering Corp, Cambridge, MA USA
[3] LabConnect LLC, Seattle, WA USA
[4] Janssen Res & Dev LLC, Spring House, PA USA
[5] Univ Penn, Dept Med, Div Hematol & Oncol, Abramson Canc Ctr, Philadelphia, PA 19104 USA
[6] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA
[7] Vrije Univ Amsterdam, Med Ctr, Dept Hematol, Amsterdam, Netherlands
来源：
BLOOD | 2015年 / 126卷 / 23期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [21] A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab
    Joseph Mikhael
    Karim Belhadj-Merzoug
    Cyrille Hulin
    Laure Vincent
    Philippe Moreau
    Cristina Gasparetto
    Ludek Pour
    Ivan Spicka
    Ravi Vij
    Jeffrey Zonder
    Djordje Atanackovic
    Nashat Gabrail
    Thomas G. Martin
    Aurore Perrot
    Samira Bensfia
    Qilong Weng
    Claire Brillac
    Dorothée Semiond
    Sandrine Macé
    Kathryn P. Corzo
    Xavier Leleu
    Blood Cancer Journal, 11
  • [22] Risk of thromboembolism in patients with multiple myeloma treated with daratumumab: a systemic review and meta-analysis
    Wang, Jiasheng
    Kim, Yeseong
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2020, 112 (05) : 650 - 657
  • [23] Disseminated Cryptococcosis in a Patient with Multiple Myeloma Treated with Daratumumab, Lenalidomide, and Dexamethasone
    Sato, Shuku
    Kambe, Emiko
    Tamai, Yotaro
    INTERNAL MEDICINE, 2019, 58 (06) : 843 - 847
  • [24] Risk of thromboembolism in patients with multiple myeloma treated with daratumumab: a systemic review and meta-analysis
    Jiasheng Wang
    Yeseong Kim
    International Journal of Hematology, 2020, 112 : 650 - 657
  • [25] Outcomes of COVID-19 in multiple myeloma patients treated with daratumumab
    Jin, Dian
    He, Jingsong
    Wu, Wenjun
    Han, Xiaoyan
    Le, Jing
    Shu, Wenxiu
    Fu, Jiaping
    Kong, Hongwei
    Wang, Gang
    Zhou, Xiujie
    Qu, Zhigang
    Cai, Zhen
    He, Donghua
    CANCER SCIENCE, 2024, 115 (01) : 237 - 246
  • [26] CD38 Expression Loss in Multiple Myeloma Treated with Daratumumab
    Hotchandani, Nihar
    Fung, Henry
    Dulaimi, Essel
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2016, 146
  • [27] Clinical Factors Associated to VTE in Multiple Myeloma Patients Treated with Daratumumab
    Subramanian, Naveen G.
    Aung, Fleur M.
    Patel, Krina
    Lee, Hans C.
    Jin, Shida
    Young, Elliana
    Hernandez, Cristhiam Mauricio Rojas
    BLOOD, 2022, 140 : 5177 - 5179
  • [28] Daratumumab for the Treatment of Multiple Myeloma
    Plesner, Torben
    Krejcik, Jakub
    FRONTIERS IN IMMUNOLOGY, 2018, 9
  • [29] NICE guidance on daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma
    Elsada, Ahmed
    Adler, Amanda I.
    LANCET ONCOLOGY, 2019, 20 (05): : 619 - 620
  • [30] Daratumumab for the treatment of multiple myeloma
    Goldsmith, S. R.
    Foley, N.
    Schroeder, M. A.
    DRUGS OF TODAY, 2021, 57 (10) : 591 - 605
12345